Advanced Brain Cancer: Tissue Freezing

Ashley Dalton Excerpts

Wednesday 7th January 2026 Westminster Hall

[The Parliamentary Under-Secretary of State for Health and Social Care (Ashley Dalton)]

It is a pleasure to serve under your chairmanship, Mr Western. I thank my hon. Friend the Member for Caerphilly (Chris Evans) and all other hon. Members for their contributions, many of which were deeply personal and moving. I thank them all for their courage and soft-heartedness, and for bringing such compassion and insight to this debate.

Let me say how sorry I was to hear about the loss of Owain at the age of just 34. His story reminds us that many people lose their lives to brain cancer very shortly after diagnosis, and we are determined to do all we can to change that. I extend my deepest sympathies to his wife Ellie, who is here today, and his daughter Amelia. I would be honoured to meet Ellie and my hon. Friend to hear more about her and Owain’s story.

Just yesterday, I was here for a debate on less survivable cancers. These debates and the petition show how much progress on cancer matters to Parliament and the public. My hon. Friend the Member for Mitcham and Morden (Dame Siobhain McDonagh) said that debates on brain cancer are a bit like buses: there are none for ages, then suddenly three at once. I want to acknowledge that her work has led to the higher profile for such debates in Parliament, more of which are taking place. I thank and commend her for her efforts in this field.

My hon. Friend the Member for Caerphilly raised incredibly serious issues about how informed consent, tissue freezing and innovation are impacting patients. I will take those points in turn. I will primarily address the context in England, although I acknowledge that areas of this policy apply across the UK. On informed consent and tissue storage, as a cancer patient myself, I find it very troubling when patients say they have not been informed about their tissue storage, as campaigners have reported. I completely understand why the Owain’s law petition calls for people to be properly informed about the choices available to them. Let me be clear: patients must always be fully informed about their rights, options and choices regarding the storage and future use of their tissue samples.

The Human Tissue Authority was established in 2004 to oversee and licence organisations in the removal, storage and use of human tissue in England, Wales and Northern Ireland. Under the Human Tissue (Quality and Safety for Human Application) Regulations 2007, consent must be sought to collect human tissues and cells that are to be used in patient treatment. The Human Tissue Authority ensures compliance against those regulations as part of its standards, inspection and licensing regime.

Consent should be sought in line with the suitable treatment options available to individual patients, which would be determined by their clinicians. That requirement extends to the collection of tumour samples that are to be used as the starting material in the manufacture of cancer vaccines. The Government expect establishments to be held to the highest standards to ensure appropriate and ethical use of human tissue. I understand that my hon. Friend is meeting with the Human Tissue Authority to discuss this matter further, and I know that he will keep me closely in the loop on that.

Owain’s law also asks for every NHS hospital to freeze suitable brain tumour tissue to allow patients to benefit from emerging cancer treatments. Individual pathology services in England have their own processes, known as standard operating procedures, for fresh freezing of tissue samples. NHS procedures mirror local capabilities, which means the capacity for fresh freezing often depends on the availability of neurosurgery services in the local area.

The human tissue regulations were introduced due to concerns that pathologists were retaining human tissues without appropriate consent. Any changes will need to be carefully considered by the Government. However, as was requested by my hon. Friend the Member for Caerphilly and the hon. Member for Strangford (Jim Shannon), I am happy to liaise with the devolved Governments on this issue, and I commit today to further exploring the current arrangements for freezing tissues and the options for change, particularly for brain tumour tissues.

Beyond improving access to emerging treatments through freezing, we know that the most effective way to improve survival rates from cancers, including brain cancers, is to catch them early. That is why we have agreed around £600 million of capital investment in diagnostics for this financial year. Over £100 million will go to histopathology services, automation and digital diagnostics to improve pathology laboratories.

[Dame Siobhain McDonagh]

I apologise for challenging the Minister’s assertion, but in the case of glioblastoma, it really does not matter how early it is detected; the consequence is the same. It is a stage 4 tumour that is going to kill the person and the average life expectancy is nine months.

[Ashley Dalton]

I note my hon. Friend’s clarification, but with that in mind, we do know that it is important to diagnose all cancers as quickly as possible, and the diagnosis of brain cancers is equally important so as to start treatment as quickly as possible. To that end, the Chancellor announced further investment in diagnostics at the autumn statement as part of a £6 billion capital investment to deliver constitutional standards.

On genomics, I met the chief scientific officer for genomics yesterday to discuss how we ensure that the UK remains a world leader in genomics—which we are—and that we can apply genomics to improve cancer outcomes. We hope that our investment in diagnostics and pathology will mean that, in future, patients such as Owain will access a greater range of treatment options.

My hon. Friend the Member for Caerphilly and Ellie are entirely right to raise the importance of innovation, particularly for less survivable cancers such as brain cancer. The Government are proud to support the Rare Cancers Bill introduced by my hon. Friend the Member for Edinburgh South West (Dr Arthur). Next Friday, Baroness Elliott will move its Second Reading in the other place.

We will go even further to ensure that all patients with brain cancer have access to cutting edge clinical trials, innovation and lifesaving treatments. As part of our action, the National Institute for Health and Care Research announced the pioneering brain tumour research consortium to accelerate research into new brain tumour treatments across the UK. The NIHR is backing the consortium with an initial £13.7 million and more money to come this year. The world-leading consortium aims to transform outcomes for adults and children who are living with brain tumours and for their families, ultimately reducing the number of lives lost to cancer. As I confirmed yesterday, I will write to my hon. Friend the Member for Mitcham and Morden in detail regarding access to funding. I am happy to commit to seeking information and exploring how we can make access to funding much clearer and more transparent.

I am pleased to confirm that the national cancer plan for England will be published in just a few short weeks, in early February. It will focus on rarer cancers, including brain cancer, and will include further details on how we will improve outcomes and work with stakeholders such as the Tessa Jowell Brain Cancer Mission to do so. The plan will detail further action to speed up diagnosis and treatment in England, ensuring that patients have access to the latest treatments and technology and ultimately driving up survival rates.

[Jim Shannon]

I thank the Minister for her comprehensive reply to all our questions. In my contribution, I mentioned that Queen’s University Belfast and the Belfast health and social care trust are doing a pilot scheme, which I hope will benefit England, Scotland and Wales. Can the Minister ask her Department’s civil servants to take that on board?

[Ashley Dalton]

I am happy to confirm that I will ask officials to look into that, and to give me some advice on that pilot and on having a conversation with those running it about what we could learn from them. I thank the hon. Member for raising that question.

I will close by paying tribute to our late colleague and Member of the Senedd, Hefin David. Through tireless campaigning, he brought Owain’s story to the Senedd. My hon. Friend the Member for Caerphilly has now brought it to this place and I thank him for that. I look forward to working with him and other hon. Members to make 2026 the year that we shift the dial for patients with brain cancer.